0001209191-21-025846.txt : 20210407 0001209191-21-025846.hdr.sgml : 20210407 20210407160840 ACCESSION NUMBER: 0001209191-21-025846 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210329 FILED AS OF DATE: 20210407 DATE AS OF CHANGE: 20210407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thornton Michael Milos CENTRAL INDEX KEY: 0001706297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37969 FILM NUMBER: 21812211 MAIL ADDRESS: STREET 1: 3600 GREEN COURT, SUITE 350 CITY: ANN ARBOR STATE: MI ZIP: 48105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENDRA Life Sciences Inc. CENTRAL INDEX KEY: 0001681682 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 260579295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3600 GREEN COURT STREET 2: SUITE 350 CITY: ANN ARBOR STATE: MI ZIP: 48105 BUSINESS PHONE: 734-335-0468 MAIL ADDRESS: STREET 1: 3600 GREEN COURT STREET 2: SUITE 350 CITY: ANN ARBOR STATE: MI ZIP: 48105 FORMER COMPANY: FORMER CONFORMED NAME: Endra Inc. DATE OF NAME CHANGE: 20160805 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-29 0 0001681682 ENDRA Life Sciences Inc. NDRA 0001706297 Thornton Michael Milos 3600 GREEN COURT, SUITE 350 ANN ARBOR MI 48105 0 1 0 0 Chief Technology Officer Common Stock 2021-03-29 4 S 0 18750 2.37 D 274960 D Common Stock 2021-04-07 4 S 0 15000 2.53 D 259960 D Stock Options 2.64 2021-04-05 4 A 0 50000 0.00 A 2031-04-05 Common Stock 50000 50000 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022. /s/ Michael M. Thornton by Mark Busch, attorney-in-fact 2021-04-07